1. Home
  2. ENTA vs IRLA Comparison

ENTA vs IRLA Comparison

Compare ENTA & IRLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

N/A

Current Price

$10.94

Market Cap

303.8M

Sector

Health Care

ML Signal

N/A

IRLA

IRulya Therapeutics Inc. Common Stock

N/A

Current Price

$39.46

Market Cap

360.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTA
IRLA
Founded
1995
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.8M
360.3M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
ENTA
IRLA
Price
$10.94
$39.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
8
Target Price
$21.83
★ $75.00
AVG Volume (30 Days)
★ 244.8K
87.8K
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 29.93
N/A
EPS
★ N/A
N/A
Revenue
★ $102,814,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 16.48
N/A
52 Week Low
$10.01
$26.90
52 Week High
$17.15
$45.00

Technical Indicators

Market Signals
Indicator
ENTA
IRLA
Relative Strength Index (RSI) 45.83 63.40
Support Level $10.01 $28.14
Resistance Level $13.94 $43.00
Average True Range (ATR) 0.80 4.03
MACD 0.08 0.71
Stochastic Oscillator 41.51 67.28

Price Performance

Historical Comparison
ENTA
IRLA

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: